Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.61 |
| ▸ | CALML3 | P27482 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612431 | 0.93 | MAOA (0.61) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6791790 | 0.93 | MAOA (0.64) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6613234 | 0.93 | MAOA (0.60) | MAOACALML3MAOBLMNAPTGS1 | |
| Hydrochloric Acid SCHEMBL6799488 | 0.93 | MAOA (0.60) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6793065 | 0.92 | MAOA (0.59) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6797219 | 0.91 | MAOA (0.58) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6612200 | 0.90 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6613809 | 0.90 | MAOA (0.64) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6796437 | 0.90 | MAOA (0.51) | MAOACALML3MAOBCYP3A4CYP2C19 | |
| SCHEMBL6792243 | 0.89 | MAOA (0.59) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | claimed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | claimed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | MAOA 763/4885CALML3 4610/4885MAOB 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.